Biogen
在场
是其中之一......
- Forbes Global 2000 (#775);
- Fortune 500 (#401);
- Nasdaq 100;
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Biogen 是一家在股票代码 BIIB (US) 下上市的公司。
Biogen 在 9 个国家有直接业务。Biogen 拥有 10家子公司，其中包括 Biogen ANZ、Biogen BeLux 和 Biogen Canada。
他们在：
涉及Biogen的并购和融资。
- Biogen has announced the acquisition of HI-Bio (公布2024七月3号).
- Biogen 已收购 Reata Pharmaceuticals (公布2023九月29号).
- Biogen has announced the acquisition of Reata Pharmaceuticals (公布2023八月1号).
高管
查看带有其 103 名主要高管的组织结构图
Biogen 搜索最多的简介
- Christopher Viehbacher, Director, President and Chief Executive Of...
- Eric Rowinsky, Director
- William Hawkins, Director
高管在Biogen变化
- Michael McDonnell, Executive Vice President and Chief Financial Officer, 将于 20252月28 退休 (新闻发布的2024十月30号).
- Robin Kramer 曾任 Senior Vice President, Chief Accounting Officer, Head of Global Business Services and Treasury, 将于 20252月28 升职为 Chief Financial Officer (新闻发布的2024十月30号).
- Menelas PangalosMenelas Pangalos 将于20251月1作为 Director 加入公司 (新闻发布的2024九月12号).
创建提醒
跟踪 Biogen 的高管变动
生物技术
Biogen 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Genus (联合王国)。
Popular M&A news in 生物技术
- Chromocell的新名称是Channel Therapeutics Corporation。 (公布2024十一月22号).
- Enveda Biosciences 刚刚宣布为 130 筹款数百万美元。 (公布2024十一月22号).
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
生物技术 行业的其他推荐联系人
消息
Biogen 的最新新闻稿
- Biogen to Report Third Quarter 2020 Financial Results October 21, 2020 | Biogen
- Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab) | Biogen
- Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab) | Biogen
- Reactive Statement to ICER’s announced plans to conduct an assessment on the value of aducanumab | Biogen
- Reactive Statement to ICER’s announced plans to conduct an assessment on the value of aducanumab | Biogen
- Biogen to Webcast Prerecorded Encore Aducanumab Presentation and Live Q&A from AAN 2020 Science Highlights on September 23, 2020 | Biogen
- Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health | Biogen
- Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health | Biogen
- New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio | Biogen
- New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS | Biogen
- View more press releases Close
通过电子邮件
